| |
| | Newswise |
 | | Newswise — Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus met™ (pioglitazone HCl and metformin HCl) is now available by prescription in pharmacies across the United States for the treatment of type 2 diabetes. |
 | | “Takeda is pleased to provide ACTOplus met, an important addition to the ACTOS family of products,” said Mark Booth, president of Takeda. |
 | | In the United States, Takeda currently markets oral diabetes, insomnia, and cholesterol-lowering treatments, and through the Takeda Global Research and Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. |
| www.newswise.com /articles/view/515753?sc=rsmn (873 words) |
|